Trial Outcomes & Findings for Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity (NCT NCT04722354)
NCT ID: NCT04722354
Last Updated: 2026-03-09
Results Overview
Adverse events will be monitored at each visit throughout the duration of the study.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
5 participants
Primary outcome timeframe
10 weeks
Results posted on
2026-03-09
Participant Flow
Participant milestones
| Measure |
Active, Then Placebo
Participants first received ABA 95 ug 2x/day for 14 days. After a washout period of 4 weeks, they then received Placebo 2x/day for 14 days.
|
Placebo, Then Active
Participants first received placebo 2x/day for 14 days. After a washout period of 4 weeks, they then received ABA 95 ug 2x/day for 14 days.
|
|---|---|---|
|
Overall Study
STARTED
|
2
|
3
|
|
Overall Study
COMPLETED
|
2
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity
Baseline characteristics by cohort
| Measure |
All Study Partcipants
n=5 Participants
All subjects randomized into the trial. All participants were randomized to receive all interventions in a crossover design
|
|---|---|
|
Age, Continuous
|
63 years
n=68 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=68 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=68 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=68 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=68 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=68 Participants
|
PRIMARY outcome
Timeframe: 10 weeksAdverse events will be monitored at each visit throughout the duration of the study.
Outcome measures
| Measure |
ABA Group
n=5 Participants
95 ug 2x/day for 14 days
|
Placebo Group
n=5 Participants
Corn Starch 300 mg for 14 days
|
|---|---|---|
|
Monitoring Adverse Events
|
0 TEAE
|
0 TEAE
|
PRIMARY outcome
Timeframe: After 2 weeks of treatmentRate of glucose disposal, measured by hyperinsulinic euglycemic clamp, normalized to pre-treatment baseline (mg/min)
Outcome measures
| Measure |
ABA Group
n=5 Participants
95 ug 2x/day for 14 days
|
Placebo Group
n=5 Participants
Corn Starch 300 mg for 14 days
|
|---|---|---|
|
Insulin Sensitivity
|
1.173 ratio to baseline
Standard Deviation 0.292 • Interval 0.808 to
|
0.905 ratio to baseline
Standard Deviation 0.075 • Interval 0.775 to 0.958
|
Adverse Events
ABA Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place